When administered, the HiB vaccine stimulates the immune system to produce antibodies against the polysaccharide capsule of the HiB bacteria. These antibodies can then recognize and neutralize the bacteria if the individual is later exposed to it. The conjugation of the polysaccharide to a protein carrier enhances the immune response by involving T-helper cells, leading to more robust and long-lasting immunity.
